STOK
Stoke Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.83B
P/E Ratio
—
EPS
$-2.86
Beta
1.20
52W High
$40.22
52W Low
$9.09
50-Day MA
$33.15
200-Day MA
$29.63
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
204.08
PEG Ratio
—
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious genetic diseases in the United States. The company is headquartered in Bedford, Massachusetts.
Fundamentals
| Revenue (TTM) | $32.08M |
| Gross Profit (TTM) | $32.08M |
| EBITDA | $-183.52M |
| Operating Margin | -858.00% |
| Return on Equity | -45.60% |
| Return on Assets | -27.20% |
| Revenue/Share (TTM) | $0.53 |
| Book Value | $6.34 |
| Price-to-Book | 4.63 |
| Price-to-Sales (TTM) | 56.96 |
| EV/Revenue | 46.33 |
| EV/EBITDA | 52.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -96.10% |
| Shares Outstanding | $62.28M |
| Float | $46.76M |
| % Insiders | 3.82% |
| % Institutions | 120.29% |
Historical Volatility
HV 10-Day
34.19%
HV 20-Day
33.14%
HV 30-Day
36.09%
HV 60-Day
50.30%
HV Rank
2.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($45.10 target)
1
Strong Buy11
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026